A Study of WVT078 in Patients With Multiple Myeloma (MM)

• Status: Recruiting
• Trial end date: 2023-12-08
• Target enrollment: 0
• Participant gender: All

Summary

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)

Exclusion Criteria:

• Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment

• Malignant disease other than being treated on this study

• Active known or suspected autoimmune disease

• Impaired cardiac function or clinically significant cardiac disease

• Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter

• Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses